| Jun 19 |
Takeda reports long-term data from Phase III CIDP treatment trial
|
| Jun 18 |
OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
|
| Jun 18 |
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
|
| Jun 17 |
Takeda’s epilepsy drug misses the mark in two Phase III trials
|
| Jun 17 |
Ovid stock plunges 66% on failed studies for soticlestat
|
| Jun 17 |
Takeda drug for rare types of epilepsy misses goal in late-stage trial
|
| Jun 17 |
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
|
| Jun 14 |
Takeda signs option agreement with Ascentage for CML drug
|
| Jun 14 |
Takeda Signs Option Agreement with Ascentage to License Leukemia Drug
|
| Jun 14 |
Takeda seeks licensing deal for blood cancer therapy
|
